




Instance: composition-en-396604b2a44a552f3c94ac2d7537f02d
InstanceOf: CompositionUvEpi
Title: "Composition for namuscla Package Leaflet"
Description:  "Composition for namuscla Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp36e358570ca5cea8d7a0bff975863672)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - namuscla"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Namuscla is and what it is used for  </li>
<li>What you need to know before you take Namuscla  </li>
<li>How to take Namuscla  </li>
<li>Possible side effects  </li>
<li>How to store Namuscla  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What namuscla is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What namuscla is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Namuscla is a medicine that contains the active substance mexiletine. </p>
<p>Namuscla is used to treat the symptoms of myotonia (when muscles relax slowly and with difficulty 
after they are used) in adults with non-dystrophic myotonic disorders, which are caused by genetic 
defects that affect muscle function.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take namuscla"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take namuscla"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Namuscla 
- if you are allergic to mexiletine or to any of the other ingredients of this medicine (listed in 
section 6) 
- if you are allergic to any local anaesthetic 
-<br />
if you have had heart attack<br />
- if your heart does not work well enough 
- if you have certain disorders of the heart rhythm 
- if your heart beats too fast 
- if the blood vessels of your heart are damaged 
- if you also take certain medicines to treat disorders of the heart rhythm (see Other medicines 
and Namuscla) 
- if you also take certain medicines which have a narrow therapeutic window (see Other 
medicines and Namuscla). </p>
<p>If you have any doubt, ask your doctor or pharmacist. </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist or nurse before taking Namuscla if you have:</p>
<ul>
<li>heart problems<br />
Internal Doc Ref: v6.6 </li>
<li>liver problems </li>
<li>kidney problems </li>
<li>low or high potassium blood levels </li>
<li>low magnesium blood levels </li>
<li>epilepsy  </li>
</ul>
<p>Heart function 
Before starting treatment with Namuscla, you will have tests to check how well your heart is working, 
including ECG (Electrocardiogram). These tests will also be performed regularly during treatment 
with Namuscla, and before and after your dose of Namuscla is modified. How often these tests will be 
performed depends on your heart function.<br />
If you or your doctor detects any heart rhythm disturbances or any of the conditions stated in section 
 Do not take Namuscla , your doctor will stop your treatment with Namuscla. </p>
<p>If you notice that the rhythm of your heart changes (the heart beats faster or slower), if you feel 
fluttering or pain in your chest, if you have difficulty breathing, if you feel dizzy, if you sweat or if 
you faint, you have to contact an emergency centre immediately. </p>
<p>Some patients may have higher blood levels of Namuscla because of slower break down in the liver 
and the dose may need to be adjusted accordingly. </p>
<p>Children and adolescents 
Namuscla should not be used in children and adolescents younger than 18 years old. </p>
<p>Other medicines and Namuscla 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.  </p>
<p>Do not take Namuscla with certain medicines for treating heart rhythm disorders (quinidine, 
procainamide, disopyramide, ajmaline, encainide, flecainide, propafenone, moricizine, amiodarone, 
sotalol, ibutilide, dofetilide, dronedarone, vernakalant). See section  Do not take Namuscla . Taking 
Namuscla together with any of these medicines increases the risk of a serious heart rhythm disturbance 
called torsades de pointes. </p>
<p>Do not take Namuscla with certain medicines which have a so called narrow therapeutic window 
(these are medicines where small differences in dose or blood concentration may impact the effect of 
the medicine or side effects). Examples of such medicines are digoxin (for heart problems), lithium 
(mood stabiliser), phenytoin (for treating epilepsy), theophylline (against asthma) and warfarin 
(against blood clots).  </p>
<p>Tell your doctor or pharmacist if you are taking any of the following since these medicines may affect 
or be affected by Namuscla:<br />
<em> medicines for heart problems (lidocaine, tocainide, propranolol, esmolol, metoprolol, atenolol, 
carvedilol, bisoprolol, nebivolol, verapamil, diltiazem),<br />
</em> certain other medicines:  * timolol for treating high pressure in the eye (glaucoma),<br />
 * certain antibiotics (ciprofloxacin, rifampicin),  * certain antidepressants (fluvoxamine),  * tizanidine (used to relax the muscles),  * metformin (used against diabetes) * omeprazole (to treat stomach ulcer and gastric acid reflux).  </p>
<p>Smoking and Namuscla 
Tell your doctor or pharmacist if you start to smoke or quit smoking while taking Namuscla because 
smoking impacts the Namuscla blood levels and your dose may need to be adjusted accordingly. </p>
<p>Internal Doc Ref: v6.6 
Namuscla with drink 
It is recommended to reduce your caffeine intake by half while on treatment with mexiletine because 
the medicine can increase caffeine levels in your blood. </p>
<p>Pregnancy and breast-feeding  </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine. If you become pregnant while taking Namuscla, 
see your doctor immediately as it is preferable not to take Namuscla while you are pregnant. If you 
become pregnant while taking Namuscla, see your doctor immediately. </p>
<p>Mexiletine passes into human milk. You should talk to your doctor about this, together you will make 
a decision whether to abstain breast-feeding or to discontinue/abstain from mexiletine therapy. </p>
<p>Driving and using machines </p>
<p>Namuscla may in rare cases cause tiredness, confusion, blurred vision: If you have these effects do not 
drive, cycle and use machines.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take namuscla"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take namuscla"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.  </p>
<p>The recommended starting dose is 1 capsule per day. The doctor will increase the dose gradually 
depending on how well the medicine is working. The maintenance dose is 1 to 3 capsules daily taken 
at regular intervals throughout the day. </p>
<p>Do not take more than 3 capsules a day. </p>
<p>Check of heart function 
Before starting treatment with Namuscla and regularly during treatment, you will have tests to check 
how well your heart is working,. Depending on your heart function you may also need testing before 
and after any dose adjustment. See section  Warnings and precautions . Your doctor will also 
regularly reassess your treatment to make sure Namuscla is still the best medicine for you. </p>
<p>Method of administration 
Namuscla is for oral use. </p>
<p>Swallow the capsule with a glass of water, while standing or sitting up. You may take Namuscla 
during a meal to avoid belly pain (see section  Possible side effects ). </p>
<p>If you take more Namuscla than you should 
Contact your doctor if you take more than the recommended dose of Namuscla. This could be very 
harmful to your health. You or your companion should contact the doctor immediately if you have 
tingling in the arms and legs, if you feel unable to think clearly or concentrate, if you have 
hallucinations, convulsions, if you feel that your heart beats slower, if you feel dizzy and faint, if you 
collapse or if your heart stops beating. </p>
<p>If you forget to take Namuscla 
If you have forgotten a dose, do not take a double dose and take the next dose at your regular schedule. </p>
<p>If you have further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
Internal Doc Ref: v6.6 
The most serious side effects are:<br />
Contact your doctor or go to your nearest emergency center immediately if you experience any of the 
following side effects:</p>
<ul>
<li>severe allergy to mexiletine (with symptoms such as severe rash with fever); this is a very rare side 
effect, may affect up to 1 in 10,000 people. </li>
<li>disorders of heart rhythm, see section  Warnings and precautions  for symptoms and more 
information; this is a common side effect, may affect up to 1 in 10 people. </li>
</ul>
<p>Other side effects that may occur: 
Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>Abdominal (belly) pain </li>
<li>Insomnia (difficulty sleeping) </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>Somnolence (sleepiness) </li>
<li>Headache </li>
<li>Tingling in the arms and legs </li>
<li>Blurred vision </li>
<li>Vertigo (sensation of feeling off balance) </li>
<li>Rapid heart rate </li>
<li>Flushing </li>
<li>Low blood pressure (which can cause dizziness and feeling faint) </li>
<li>Nausea (feeling sick) </li>
<li>Acne </li>
<li>Pain in the arms and legs </li>
<li>Tiredness </li>
<li>Weakness </li>
<li>Chest discomfort </li>
<li>Malaise (a feeling of general discomfort and illness) </li>
</ul>
<p>Uncommon side effects (may affect up to 1 in 100 people):</p>
<ul>
<li>Convulsions (fits) </li>
<li>Speech disorders </li>
<li>Slow heart rate </li>
</ul>
<p>Rare side effects (may affect up to 1 in 1,000 people):</p>
<ul>
<li>Abnormal functioning of the liver (observed after blood analysis). </li>
</ul>
<p>Very rare side effects (may affect up to 1 in 10,000 people):</p>
<ul>
<li>Liver injury including inflammation (hepatitis) </li>
<li>Severe reaction to the medicine (with rash and fever) </li>
</ul>
<p>Not known (frequency cannot be estimated from the available data):</p>
<ul>
<li>Decrease in white blood cells or in platelets  </li>
<li>Lupus syndrome (disease of the immune system) </li>
<li>Redness and peeling of the skin  </li>
<li>Stevens-Johnson syndrome: a severe allergic reaction with skin rashes, often in the form of blisters 
and sores in the mouth and eyes, and other mucous membranes </li>
<li>Blisters of the skin, malaise and fever in the context of a condition called DRESS </li>
<li>Hallucinations (seeing or hearing something that is not present). </li>
<li>Transient confusion (a temporary inability to think clearly or concentrate) </li>
<li>Double vision </li>
<li>Altered sense of taste </li>
<li>Disorders of heart rhythm </li>
<li>Collapse </li>
<li>Hot flushes 
Internal Doc Ref: v6.6 </li>
<li>Pulmonary fibrosis (disease of the lung) </li>
<li>Diarrhoea </li>
<li>Vomiting </li>
<li>Injury of the oesophagus (food pipe) </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store namuscla"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store namuscla"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.  </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date 
refers to the last day of that month. </p>
<p>Store below 30 C. Store in the original package in order to protect from moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Namuscla contains<br />
Each hard capsule contains:</p>
<ul>
<li>mexiletine hydrochloride corresponding to 166.62 mg of mexiletine (active substance) </li>
<li>Other ingredients (maize starch, colloidal anhydrous silica, magnesium stearate, gelatin, iron 
oxide [E 172], titanium dioxide [E 171]).  </li>
</ul>
<p>What Namuscla looks like and contents of the pack 
Namuscla hard capsules are reddish hard gelatin capsules filled with white powder. 
Namuscla is available in blister packs containing 30, 50, 100 or 200 capsules. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Lupin Europe GmbH 
Hanauer Landstra e 139-143,<br />
60314 Frankfurt am Main 
Germany </p>
<p>Manufacturer 
Hormosan Pharma GmbH 
Hanauer Landstra e 139-143,<br />
60314 Frankfurt am Main 
Germany </p>
<p>Lupin Healthcare (UK) Ltd 
The Urban Building, second floor, 3-9 Albert Street 
SL1 2BE Slough, Berkshire,<br />
United Kingdom </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
Internal Doc Ref: v6.6 
AT, BE, BG, CZ, CY, DK, EE, EL, ES, FR, 
FI, HR, IE, IS, IT, LV, LT, LU, HU, MT, NL, 
NO, PL, PT, RO, SI, SK, SE 
DE </p>
<p>Lupin Europe GmbH 
Tel: +49 69 96759Email: customerserviceLEG@lupin.com  </p>
<p>Lupin Europe GmbH 
Tel: +49 (0) 800 182 4Email: customerserviceLEG@lupin.com </p>
<p>UK </p>
<p>Lupin Europe GmbH 
Tel: +44 (0) 800-088-5Email: customerserviceLEG@lupin.com </p>
<p>This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-396604b2a44a552f3c94ac2d7537f02d
InstanceOf: CompositionUvEpi
Title: "Composition for namuscla Package Leaflet"
Description:  "Composition for namuscla Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp36e358570ca5cea8d7a0bff975863672)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - namuscla"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Namuscla<br />
3. Sådan skal du tage Namuscla<br />
4. Bivirkninger<br />
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What namuscla is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What namuscla is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Namuscla er et lægemiddel, som indeholder det aktive stof mexiletin. </p>
<p>Namuscla bruges til at behandle symptomer på myotoni (når musklerne er lang tid om og har svært 
ved at slappe af efter brug) hos voksne med ikke-dystrofiske myotone muskelsygdomme, som er 
forårsaget af genetiske defekter, der påvirker muskelfunktion.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take namuscla"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take namuscla"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Namuscla 
- hvis du er allergisk over for mexiletin eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i punkt 6) 
- hvis du er allergisk over for noget lokalt bedøvelsesmiddel 
-<br />
hvis du har haft et hjerteanfald<br />
- hvis dit hjerte ikke virker godt nok 
- hvis du har visse hjerterytmeforstyrrelser 
- hvis din puls er for hurtig 
- hvis blodkarrene i dit hjerte er beskadigede 
- hvis du også tage visse lægemidler til behandling af hjerterytmeforstyrrelser (se "Brug af anden 
medicin sammen med Namuscla") 
- hvis du også tager visse lægemidler med et snævert terapeutisk vindue (se "Brug af anden 
medicin sammen med Namuscla") </p>
<p>Spørg din læge eller apotekspersonalet, hvis der er noget du er i tvivl om. </p>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen, apotekspersonalet eller sundhedspersonalet, før du tager Namuscla, hvis du har:</p>
<ul>
<li>problemer med hjertet  </li>
<li>problemer med leveren </li>
<li>problemer med nyrerne </li>
<li>lavt eller højt kaliumniveau i blodet </li>
<li>lavt magnesiumniveau i blodet </li>
<li>epilepsi  </li>
</ul>
<p>Hjertefunktion 
Inden du starter behandling med Namuscla, vil du få foretaget undersøgelser for at kontrollere, hvor 
godt dit hjerte virker, herunder ekg (elektrokardiogram). Disse undersøgelser vil desuden blive 
foretaget regelmæssigt under behandling med Namuscla samt før og efter en tilpasning af din dosis 
Namuscla. Hvor ofte disse undersøgelser vil blive foretaget, afhænger af din hjertefunktion.<br />
Hvis du eller din læge bemærker nogen hjerterytmeforstyrrelser eller nogen af tilstandene angivet i 
afsnittet "Tag ikke Namuscla", vil din læge stoppe din behandling med Namuscla. </p>
<p>Hvis du bemærker, at din hjerterytme ændrer sig (hjertet slår hurtigere eller langsommere), fornemmer 
hjertebanken eller smerter i brystet, har vejrtrækningsbesvær, føler dig svimmel, sveder eller besvimer, 
skal du straks kontakte en akutklinik </p>
<p>Nogle patienter kan få højere niveauer af Namuscla i blodet pga. en langsommere nedbrydning i 
leveren, og dosis skal muligvis tilpasses dette. </p>
<p>Børn og unge 
Namuscla må ikke anvendes til børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Namuscla 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig.  </p>
<p>Tag ikke Namuscla sammen med visse andre lægemidler til behandling af hjerterytmeforstyrrelser 
(quinidin, procainamid, disopyramid, ajmalin, encainid, flecainid, propafenon, moricizin, amiodaron, 
sotalol, ibutilid, dofetilid, dronedaron, vernakalant). Se punktet "Tag ikke Namuscla". Samtidig 
indtagelse af Namuscla og nogen af disse lægemidler øger risikoen for en alvorlig 
hjerterytmeforstyrrelse kaldet torsade de pointes.  </p>
<p>Tag ikke Namuscla sammen med visse lægemidler, der har et såkaldt snævert terapeutisk vindue 
(lægemidler hvor en lille forskel i dosis eller koncentration i blodet kan påvirke effekten af medicinen 
eller give bivirkninger). Eksempler på sådanne lægemidler er digoxin (mod hjerteproblemer), lithium 
(humørstabilisator), phenytoin (mod epilepsi), theophyllin (mod astma) og wafarin (mod blodpropper). </p>
<p>Fortæl lægen eller apotekspersonalet, hvis du tager en eller flere af følgende, eftersom disse 
lægemidler kan påvirke eller blive påvirket af Namuscla: </p>
<ul>
<li>
<p>medicin for hjerteproblemer (lidocain, tocainid, propranolol, esmolol, metoprolol, atenolol, 
carvedilol, bisoprolol, nebivolol, verapamil, diltiazem)  </p>
</li>
<li>
<p>visse andre lægemidler:  * 
timolol til behandling af højt tryk i øjet (glaukom)  * 
visse antibiotika (ciprofloxacin, rifampicin)  * 
visse antidepressiva (fluvoxamin)  * 
tizanidin (bruges til afslapning af musklerne) * 
metformin (bruges til behandling af diabetes) * 
omeprazol (til behandling af mavesår og mavesyre-reflux (kan vise sig ved sure opstød, 
halsbrand eller sviende smerter i maven)). </p>
</li>
</ul>
<p>Rygning og Namuscla 
Fortæl din læge eller apotekspersonalet hvis du begynder eller holder op med at ryge, mens du tager 
Namuscla, da rygning påvirker niveauet af Namuscla i blodet, og din dosis muligvis skal tilpasses. </p>
<p>Namuscla med drikkevarer 
Det anbefales, at du reducerer dit indtag af koffein med halvdelen under behandling med mexiletin, da 
lægemidlet kan øge niveauerne af koffein i blodet. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel. Hvis du bliver gravid, mens du tager 
Namuscla, skal du straks kontakte lægen, da det ikke er tilrådeligt at tage Namuscla, mens du er 
gravid.. </p>
<p>Mexiletin udskilles i human mælk. Du skal tale med din læge om dette, så I sammen kan beslutte, 
omdu skal undlade at amme eller stoppe/afholde dig fra behandling med mexiletin. </p>
<p>Trafik- og arbejdssikkerhed 
Namuscla kan i sjældne tilfælde forårsage træthed, forvirring, sløret syn: Undlad at køre, cykle og 
betjene maskiner, hvis du oplever disse effekter.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take namuscla"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take namuscla"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet.  </p>
<p>Den anbefalede startdosis er 1 kapsel per dag. Lægen vil gradvist øge dosen afhængig af, hvor godt 
lægemidlet virker. Vedligeholdelsesdosen er 1 til 3 kapsler dagligt taget med regelmæssige 
mellemrum hele dagen. </p>
<p>Tag ikke mere end 3 kapsler dagligt. </p>
<p>Undersøgelse af hjertefunktion 
Inden opstart af behandling med Namuscla og løbende under behandlingen, skal du undersøges for at 
se, hvor godt dit hjerte fungerer. Afhængigt af din hjertefunktion skal du muligvis også testes før og 
efter en tilpasning af dosis. Se afsnittet "Advarsler og forsigtighedsregler". Din læge vil også 
regelmæssigt revurdere din behandling for at sikre, at Namuscla stadig er det bedste lægemiddel til 
dig. </p>
<p>Indtagelsesmetode 
Namuscla er til oral anvendelse. </p>
<p>Slug kapslen i stående eller siddende stilling med et glas vand. Du kan tage Namuscla med et måltid 
for at undgå mavesmerter (se punktet "Bivirkninger"). </p>
<p>Hvis du har taget for meget Namuscla 
Kontakt lægen, hvis du tager mere end den anbefalede dosis af Namuscla. Det kan være meget 
skadeligt for dit helbred. Du eller din ledsager skal straks kontakte lægen, hvis du mærker prikken i 
armene eller benene, hvis du ikke kan tænke klart eller koncentrere dig, hvis du har hallucinationer 
eller kramper, hvis du føler, at din puls bliver langsommere, hvis du føler dig svimmel og svag, hvis 
du kollapser, eller hvis dit hjerte stopper. </p>
<p>Hvis du har glemt at tage Namuscla 
Hvis du har glemt en dosis, må du ikke tage en dobbeltdosis som erstatning, men skal tage den næste 
dosis på det sædvanlige planlagte tidspunkt. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De mest alvorlige bivirkninger er:<br />
Kontakt straks din læge eller tag til den nærmeste skadestue, hvis du oplever disse bivirkninger:</p>
<ul>
<li>alvorlig allergi over for mexiletin (med symptomer såsom alvorligt udslæt med feber); denne 
bivirkning ses meget sjældent og kan påvirke op til 1 ud af 10.000 personer. </li>
<li>hjerterytmeforstyrrelser; dette er en almindelig bivirkning og kan påvirke op til 1 ud af 10 personer. 
Se afsnittet "Advarsler og forsigtighedsregler" for symptomer og mere information. </li>
</ul>
<p>Andre bivirkninger, der kan opstå: </p>
<p>Meget almindelige bivirkninger (kan påvirke flere end 1 ud af 10 personer):</p>
<ul>
<li>Mavesmerter </li>
<li>Søvnløshed (søvnbesvær) </li>
</ul>
<p>Almindelige bivirkninger (kan påvirke op til 1 ud af 10 personer):</p>
<ul>
<li>Somnolens (søvnighed) </li>
<li>Hovedpine </li>
<li>Prikken i arme og ben </li>
<li>Sløret syn </li>
<li>Svimmelhed </li>
<li>Hurtig hjertefrekvens </li>
<li>Blussen </li>
<li>Lavt blodtryk (som kan forårsage svimmelhed og svaghed) </li>
<li>Kvalme </li>
<li>Akne </li>
<li>Smerter i arme eller ben </li>
<li>Træthed </li>
<li>Svaghed </li>
<li>Ubehag i brystet </li>
<li>Utilpashed (en almen følelse af ubehag og sygdom) </li>
</ul>
<p>Ikke almindelige bivirkninger (kan påvirke op til 1 ud af 100 personer):</p>
<ul>
<li>Kramper (anfald) </li>
<li>Taleforstyrrelser </li>
<li>Langsom puls </li>
</ul>
<p>Sjældne bivirkninger (kan påvirke op til 1 ud af 1.000 personer):</p>
<ul>
<li>Unormal leverfunktion (set efter analyse af blodet) </li>
</ul>
<p>Meget sjældne bivirkninger (kan påvirke op til 1 ud af 10.000 personer):</p>
<ul>
<li>Leverskade inklusive betændelse (hepatitis) </li>
<li>Alvorlig reaktion på lægemidlet (med udslæt og feber) </li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke bestemmes ud fra de tilgængelige data) 
- Reduceret antal hvide blodlegemer eller blodplader<br />
- Lupussyndrom (sygdom i immunsystemet) 
- Rødme og afskalning af huden<br />
- Stevens-Johnsons syndrom: en alvorlig allergisk reaktion med hududslæt, ofte i form af blærer og sår 
i mund, øjne og andre slimhinder 
- Blærer på huden, utilpashed og feber i forbindelse med en tilstand kaldet DRESS. 
- Hallucinationer (at se eller høre noget som ikke er tilstede) 
- Forbigående forvirring (midlertidig manglende evne til at tænke klart eller koncentrere sig) 
- Dobbeltsyn 
- Ændret smagssans 
- Hjerterytmeforstyrrelser 
- Kollaps 
- Hedeture 
- Lungefibrose (lungesygdom) 
- Diarré 
- Opkastning 
- Skade i øsofagus (spiserøret) </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apoteket. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store namuscla"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store namuscla"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.  </p>
<p>Tag ikke dette lægemiddel efter den udløbsdato, der står på kartonen og blisteren efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C. Opbevares i den originale yderpakning for at 
beskytte mod fugt. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Namuscla indeholder:<br />
Hver hård kapsel indeholder:</p>
<ul>
<li>Aktivt stof: mexiletinhydrochlorid svarende til 166.62 mg mexiletin. </li>
<li>Øvrige indholdsstoffer: majsstivelse, kolloid vandfri silica, magnesiumstearat, gelatine, jernoxid 
(E 172), titandioxid (E 171).  </li>
</ul>
<p>Udseende og pakningsstørrelser 
Namuscla hårde kapsler er rødlige hårde gelatinekapsler fyldt med hvidt pulver. 
Namuscla fås i blisterpakninger med 30, 50, 100 eller 200 kapsler. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Lupin Europe GmbH 
Hanauer Landstraße 139-143<br />
60314 Frankfurt am Main 
Tyskland </p>
<p>Fremstiller 
Hormosan Pharma GmbH 
Hanauer Landstraße 139-143<br />
60314 Frankfurt am Main 
Tyskland </p>
<p>Lupin Healthcare (UK) Ltd 
The Urban Building, second floor, 3-9 Albert Street 
SL1 2BE Slough, Berkshire<br />
Storbritannien </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:  </p>
<p>AT, BE, BG, CZ, CY, DK, EE, EL, ES, FR, 
FI, HR, IE, IS, IT, LV, LT, LU, HU, MT, NL, 
NO, PL, PT, RO, SI, SK, SE 
DE </p>
<p>Lupin Europe GmbH 
Tel: +49 69 96759Email: customerserviceLEG@lupin.com  </p>
<p>Lupin Europe GmbH 
Tel: +49 (0) 800 182 4Email: customerserviceLEG@lupin.com </p>
<p>UK </p>
<p>Lupin Europe GmbH 
Tel: +44 (0) 800-088-5Email: customerserviceLEG@lupin.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-396604b2a44a552f3c94ac2d7537f02d
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for namuscla Package Leaflet for language en"
Description: "ePI document Bundle for namuscla Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-396604b2a44a552f3c94ac2d7537f02d"
* entry[0].resource = composition-en-396604b2a44a552f3c94ac2d7537f02d

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp396604b2a44a552f3c94ac2d7537f02d"
* entry[=].resource = mp396604b2a44a552f3c94ac2d7537f02d
                            
                    
Instance: bundlepackageleaflet-da-396604b2a44a552f3c94ac2d7537f02d
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for namuscla Package Leaflet for language da"
Description: "ePI document Bundle for namuscla Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-396604b2a44a552f3c94ac2d7537f02d"
* entry[0].resource = composition-da-396604b2a44a552f3c94ac2d7537f02d

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp396604b2a44a552f3c94ac2d7537f02d"
* entry[=].resource = mp396604b2a44a552f3c94ac2d7537f02d
                            
                    



Instance: mp396604b2a44a552f3c94ac2d7537f02d
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Namuscla 167 mg hard capsules"
Description: "Namuscla 167 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/18/1325/001 - 004"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Namuscla 167 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 396604b2a44a552f3c94ac2d7537f02dListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "namuscla"

* status = #current
* mode = #working

* title = "List of all ePIs associated with namuscla"

* subject = Reference(mp36e358570ca5cea8d7a0bff975863672)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#namuscla "namuscla"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-396604b2a44a552f3c94ac2d7537f02d) // namuscla en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-396604b2a44a552f3c94ac2d7537f02d) // namuscla da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-396604b2a44a552f3c94ac2d7537f02d
InstanceOf: List

* insert 396604b2a44a552f3c94ac2d7537f02dListRuleset
    